RE: A collaborative approach17 Feb 2021 16:15
A very good endorsement..
"There are studies whose results could benefit patients with moderate COVID-19 infections, in particular from small, nimble biotech firms. For example, whilst the SOLIDARITY study questioned the effectiveness of interferon beta 1a when administered subcutaneously, other studies using interferon beta are showing more promising results. This year, biotech Synairgen started a global Phase III trial using an inhaled formulation of interferon beta developed at Southampton University Hospital. A dose of the protein delivered via a nebuliser to the lungs looks to trigger an antiviral response. Earlier clinical trials conducted by Synairgen have shown that it can stimulate an immune response even in patients whose immune system is already weak, which could help patients with asthma and other chronic lung conditions. The earlier Phase II trial was focused more on a moderate COVID-19 phenotype, although the latest study has a broader scope and will include hospital and home settings."